DNA methyltransferases (DNMTs) are enzymes that add methyl groups to DNA, influencing which genes are active or silenced. Because abnormal DNMT activity is a hallmark of many cancers, measuring this activity provides important clues about how tumors grow, evade immune responses, and resist therapies.
Insights from a New Study
In a Nature Communications article, researchers examined hepatocellular carcinoma (HCC), the most common form of liver cancer. Their central finding was that a subset of “metabolic archetype” cancer cells generates harmful oxidized lipids (oxLDL), which in turn reprogram nearby immune cells called macrophages. Instead of attacking the tumor, these macrophages suppress T-cell responses, creating an environment where the cancer can thrive and resist immunotherapy. This work shed light on how metabolism and immune dysfunction are tightly linked in liver cancer progression.
Why Examine DNMT?
While the main focus of the study was on metabolism and immune crosstalk, the team also wanted to determine whether epigenetic changes were part of this process. By measuring DNMT activity in nuclear extracts, they could assess whether DNA methylation machinery shifted alongside the tumor’s metabolic state and immune-suppressive features. To do this, they used EpigenTek’s EpiQuik™ DNMT Activity/Inhibition Assay Ultra Kit, a reliable colorimetric assay that allowed rapid and sensitive quantification of DNMT enzyme activity.
What the Results Revealed
Through DNMT activity analysis, Western blot, and co-immunoprecipitation experiments, the researchers showed that oxLDL enhanced the interaction between DNMT3A and CEBPα, leading to altered DNA methylation at immune gene promoters such as Trem2 and Spp1. This finding provided a direct mechanistic link between metabolic stress, immune suppression, and epigenetic regulation in HCC.
The Added Value of Epigenetic Analysis
Including DNMT activity analysis gave the researchers an additional layer of insight: it suggested that the tumor’s ability to reprogram its environment was not just metabolic and immunological, but also tied to epigenetic regulation. This strengthens the view that cancer is a multi-dimensional disease, shaped by overlapping biological systems.
How EpigenTek Can Help
For researchers aiming to explore DNMT activity and beyond, EpigenTek offers a complete suite of tools. Our DNA Methyltransferase (DNMT) & Demethylase Assays provide a quick, sensitive, and convenient way to measure total activity or inhibition of DNMTs, TETs, and other enzymes from both purified enzyme and nuclear extract samples.
To support reliable results, we also provide complementary products such as nuclear extraction kits, global DNA methylation quantification assays, histone modification assays, and metabolism-focused antibodies. Together, these solutions give researchers a powerful platform to connect metabolic and epigenetic pathways, offering deeper insights into development, disease, and therapeutic discovery.



Cart (0)









